[{"id":"60cbbf60-fede-4d4f-85df-bafb54b1717c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01152398","created_at":"2021-01-18T04:35:15.373Z","updated_at":"2024-07-02T16:37:01.896Z","phase":"Phase 1","brief_title":"A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy","source_id_and_acronym":"NCT01152398","lead_sponsor":"Bavarian Nordic","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MVA-BN-HER2"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2019-03-14"},{"id":"c293b653-2969-42ad-a781-d4ba68e58b3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00485277","created_at":"2021-01-18T01:44:04.950Z","updated_at":"2024-07-02T16:37:01.913Z","phase":"Phase 1","brief_title":"A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer","source_id_and_acronym":"NCT00485277","lead_sponsor":"Bavarian Nordic","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MVA-BN-HER2"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":" Completion: 09/01/2010","study_completion_date":" 09/01/2010","last_update_posted":"2019-03-14"}]